<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749524</url>
  </required_header>
  <id_info>
    <org_study_id>MOCR</org_study_id>
    <nct_id>NCT04749524</nct_id>
  </id_info>
  <brief_title>Otoacoustic Emission Suppression Study</brief_title>
  <official_title>Otoacoustic Emission Suppression in Clinical Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intelligent Hearing Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intelligent Hearing Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of this project is on a physiologic auditory response called the Medial&#xD;
      Olivocochlear Reflex (MOCR) that assesses peripheral neural function. While neural hearing&#xD;
      loss is a significant auditory disorder in patients of all ages, more than 50% of newborn&#xD;
      infants are screened with a technology that is not sensitive to abnormalities in neural&#xD;
      function. The development of a time-efficient and sensitive test system to assess the MOCR&#xD;
      will provide significant benefit to infants and patients of all ages with neural deficits who&#xD;
      would otherwise go undetected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to develop an optimized hearing testing method using&#xD;
      otoacoustic emissions, that can be used to efficiently assess peripheral neural function&#xD;
      (including retrocochlear disorders) using the medial olivocochlear reflex (MOCR). Measuring&#xD;
      neural function via the MOCR. This reflex has been shown to be abnormal in patients with&#xD;
      neural disorders. The focus of this project will be the development of a screening method&#xD;
      that incorporates OAE screening and measurement of the MOCR in the same test procedure. The&#xD;
      target population in the proposed research is infants, particularly those in environments&#xD;
      where auditory brainstem response (ABR) screening is not performed routinely. Addition of the&#xD;
      MOCR to screening where ABR is not performed will address the shortcoming of OAE screening&#xD;
      which misses neural forms of hearing loss.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Otoacoustic Suppression Measure</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>The amplitude of the otoacoustic emission response will be measured when recorded with and without a suppression noise.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Neonatal Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Newborns</arm_group_label>
    <description>Otoacoustic Emissions to be measured with and without suppression noise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newborns failing initial hearing screening test</arm_group_label>
    <description>Otoacoustic Emissions to be measured with and without suppression noise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults with normal hearing</arm_group_label>
    <description>Otoacoustic Emissions to be measured with and without suppression noise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults with hearing loss</arm_group_label>
    <description>Otoacoustic Emissions to be measured with and without suppression noise</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measurement of Otoacoustic Emissions with and without suppression noise</intervention_name>
    <description>Otoacoustic emissions will be recorded using an ear probe with and without a suppression noise.</description>
    <arm_group_label>Adults with hearing loss</arm_group_label>
    <arm_group_label>Adults with normal hearing</arm_group_label>
    <arm_group_label>Newborns</arm_group_label>
    <arm_group_label>Newborns failing initial hearing screening test</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults and newborns with normal middle ear function and no external ear abnormalities such&#xD;
        as atresia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal middle-ear function&#xD;
&#xD;
          -  Present TEOAEs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atresia or other external ear abnormalities not allowing recording of OAEs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda J Hood, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael E Delgado, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intelligent Hearing Systems Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical School</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hood LJ, Berlin CI, Bordelon J, Rose K. Patients with auditory neuropathy/dys-synchrony lack efferent suppression of transient evoked otoacoustic emissions. J Am Acad Audiol. 2003 Aug;14(6):302-13.</citation>
    <PMID>14552424</PMID>
  </reference>
  <reference>
    <citation>Hood LJ, Berlin CI, Hurley A, Cecola RP, Bell B. Contralateral suppression of transient-evoked otoacoustic emissions in humans: intensity effects. Hear Res. 1996 Nov 1;101(1-2):113-8.</citation>
    <PMID>8951438</PMID>
  </reference>
  <reference>
    <citation>James AL. The assessment of olivocochlear function in neonates with real-time distortion product otoacoustic emissions. Laryngoscope. 2011 Jan;121(1):202-13. doi: 10.1002/lary.21078.</citation>
    <PMID>21181985</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The results from the project will be shared by presenting results at scientific conferences and publishing results in scientific journals. In addition, a de-identified database containing subject gender, age at recording, raw MOCR recordings, recording parameters and spectral analysis parameters will be maintained. The data will be shared with other centers conducting similar research under appropriate IRB approval.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

